Recent work has highlighted that amorphous solid dispersions (ASDs) containing
delamanid (DLM) and an enteric polymer, hypromellose phthalate (HPMCP), appear to be …

We report that the stability of amorphous clofazimine (CFZ) against crystallization is vastly
improved by salt formation with a polymer without sacrificing dissolution rate. A simple slurry …

Preventing crystallization is a primary concern when developing amorphous drug
formulations. Recently, atomic layer coatings (ALCs) of aluminum oxide demonstrated …

Physical instability remains a major concern with amorphous solid dispersions (ASDs). In
addition to bulk crystallization inhibition, another potential strategy to improve the physical …

Nanocoating is a layer or coating on various drug delivery systems and medical devices
within the nanometer range to improve the physicochemical properties, stability …

Abstract Lumefantrine (LMF), a high-mobility and easy-to-crystallize WHO drug for treating
malaria, can form an amorphous salt with poly (acrylic acid)(PAA) that is remarkably stable …

Amorphous formulations provide a general approach to improving the solubility and
bioavailability of drugs. Amorphous medicines for global health should resist crystallization …

The distinction between surface and bulk crystallization of amorphous pharmaceuticals, as
well as the importance of surface crystallization for pharmaceutical performance, is …

Amorphous drug nanoplex represents one of the most promising solubility enhancement
strategies of poorly-soluble drugs. Solubility enhancement capability of nanoplex hitherto …

Inhibiting surface crystallization is an interesting strategy to enhance the physical stability of
amorphous solid dispersions (ASDs), still preserving high drug loads. The aim of this study …